Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-12-09

Clinical Trial Update: Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia [NA]

View source ↗

Summary

Open-label study investigating intranasal oxytocin for schizophrenia has terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • intranasal oxytocin (oxytocin)

Snippet

Sponsor: University of California, San Diego | Conditions: Schizophrenia | NA | Status: TERMINATED | Results posted: 2019-12-09